Fibromyalgia is a painful, debilitating condition that affects at least 2% of the worldwide population – this equates to more than 6 million sufferers in the U.S. alone

Only a minority of patients achieve substantial symptom relief from the three currently approved medicines; alternative treatment options are urgently needed

• Initial studies using low dose oral naltrexone to treat Fibromyalgia have yielded encouraging results with the majority of patients experiencing significant symptomatic benefit [ref: Current Pain and Headache Reports (2020) 24: 64].
• Despite this data, the generic status of oral naltrexone has made a subsequent development program in Fibromyalgia commercially unviable. By developing a new transdermal formulation tailored for Fibromyalgia patients – Libero’s ambition is to finally bring a licensed naltrexone product to market for these patients.

Crohn’s disease is an incurable inflammatory bowel disease that can result in numerous serious complications that often require hospital admission and surgery including intestinal obstruction, fistulas and abscess, and if present in the colon carries and increase risk of colon cancer.

Over 500,000 American are affected, and the prevalence is on the rise for reasons that are not understood.

• An array of treatments are used to control pain, suppress inflammation and maintain periods of remission. With moderate to severe disease, injected biologic medicines are used.
• Promising early studies using low dose oral naltrexone in Crohn’s has demonstrated marked improvement in symptoms versus placebo – in both adults and children [ref Dig Dis Sci. 2011 July ; 56(7): 2088–2097, J Clin Gastroenterol. 2013 Apr;47(4):339-45], including some evidence of improved endoscopic appearance. As with Fibromyalgia however, despite encouraging early data a licensed product has not materialised.